Q2
ARTV — Q2 2026 Financial Report Analysis
Artiva's Q2 net loss widened to $25.0M as AlloNK autoimmune trials grew, but early refractory-RA data, FDA agreement on a single Phase 3 trial and a $282.7M net raise left $349.4M in cash, enough to fund operations into 2029.